Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00901914
Other study ID # VO59.08
Secondary ID 2007-007869-21
Status Completed
Phase Phase 2
First received April 28, 2009
Last updated June 26, 2013
Start date October 2008
Est. completion date August 2009

Study information

Verified date February 2010
Source Stallergenes
Contact n/a
Is FDA regulated No
Health authority Finland: Finnish Medicines AgencyPoland: Ministry of HealthFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Lithuania: State Medicine Control Agency - Ministry of HealthRussia: Ministry of Health of the Russian FederationSweden: Medical Products AgencyDenmark: Danish Medicines AgencyGermany: Paul-Ehrlich-Institut
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of three doses of r Bet v1 administered as sublingual tablets in birch pollen allergic subjects.


Recruitment information / eligibility

Status Completed
Enrollment 483
Est. completion date August 2009
Est. primary completion date June 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Symptomatic birch pollen-related allergic rhinoconjunctivitis for at least the last 2 pollen seasons

- Sensitisation to birch pollen as demonstrated, at screening, by a positive SPT to birch pollen with wheal diameter greater than 3 mm and specific IgE levels > 0.70 kU/L (birch pollen and rBet v 1)

- Patients asymptomatic to all other allergens during the birch pollen season

- RRTSS during the previous pollen season = 12 out of a maximum possible score of 18

- Patients with an FEV1 = 80% of the predicted value

- Female patients with no childbearing potential

- Female patients of childbearing potential are eligible if they are not sexually active or if they use a medically accepted contraceptive method and have a negative urine pregnancy test, and are willing and able to sign written informed consent stating that they will use appropriate contraception and not plan a pregnancy during this study

- Patients able to be compliant with respect to the completion of the daily record card and taking of the investigational products

- Patients having provided signed informed consent

Exclusion Criteria:

- Patients with symptoms of rhinoconjunctivitis during the birch pollen season due to non-birch-related allergens

- Patients with symptomatic allergic rhinitis/rhinoconjunctivitis due to house dust mites

- Patients with symptomatic allergic rhinitis/rhinoconjunctivitis due to cat or dog allergens, and living with these animals at home or at risk of frequent contacts with these animals (family, friends etc.) during the course of the study

- Patients who previously received desensitisation treatment to birch pollen and/or another Betulaceae sp. within the previous 10 years

- Patients with asthma (except birch seasonal asthma in which case the patient could be included in the study)

- Patients with any nasal or oral condition that could interfere with efficacy or safety assessments (such as nasal polyposis or oral inflammation)

- Patients with a past or current disease, which as judged by the investigator, may affect the patient's participation in or outcome of this study

- Any disease or condition which would place a patient at undue risk by being included in the study (according to the investigator's opinion)

- Usual contra-indications of immunotherapy such as concomitant local or systemic beta-blocker therapy and/or immunosuppressive drugs

- Patients with ongoing treatment by immunotherapy with another allergen

- Patients treated with inhaled/systemic steroids within 4 weeks prior to Screening, or with long acting systemic corticosteroids 12 weeks before Screening

- Patients under continuous corticotherapy or undergoing chronic treatment with H2-antihistamine drugs

- Known hypersensitivity to mannitol

- Pregnancy, breast-feeding/lactation or sexually active women of childbearing potential who are not using a medically accepted contraceptive method

- Patients with a history of drug or alcohol abuse

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
Placebo
One sublingual tablet of matching placebo daily during approximately 5.5 months
rBet v 1
One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months
rBet v 1
One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months
rBet v 1
One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months

Locations

Country Name City State
Denmark National University Hospital - Allergy Unit 4222 Copenhagen
Finland Helsingin yliopistollinen keskussairaala Helsinki
France NHC, Hôpitaux Universitaires de Strasbourg Strasbourg
Germany Charité universitaetsmedizin Berlin
Lithuania Public Institution Kaunas Medical University Hospital Kaunas
Poland SPZOZ Uniwersytecki Szpital Kliniczny Nr 1im.N.Barlickiego w Uniwersystetu Medycznego w Lodzi Lodz
Russian Federation Institute of Immunology of FMBA Moscow
Sweden Sabina RAK Gothenburg

Sponsors (3)

Lead Sponsor Collaborator
Stallergenes Aptuit Inc., Quintiles, Inc.

Countries where clinical trial is conducted

Denmark,  Finland,  France,  Germany,  Lithuania,  Poland,  Russian Federation,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Average Adjusted Symptom Score ~1 month (whole birch pollen season) No
Secondary Average Rhinoconjunctivitis Total symptom Score ~1 month (whole birch pollen season) No
Secondary Rescue Medication Score ~1 month (whole birch pollen season) No
Secondary Average Combined Score ~1 month (whole birch pollen season) No
Secondary Proportion of symptom-controlled days ~1 month (whole birch pollen season) No
Secondary Global evaluation by the patient after 5-6 months of treatment No
Secondary Immunological markers (IgE and IgG4) 6-7 months No
Secondary Sensitisation status At least 6 months No
Secondary Lower airways symptoms ~1 month (whole birch pollen season) No
Secondary Safety assessments 6-7 months Yes
See also
  Status Clinical Trial Phase
Terminated NCT01337323 - Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting N/A
Completed NCT00851344 - Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo Phase 2
Completed NCT00537355 - An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber Phase 2
Completed NCT00501527 - Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense Phase 2
Completed NCT00422149 - Twin SUBLIVAC® Grasses Clinical Efficacy Study Phase 3
Completed NCT00542607 - Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis Phase 4
Completed NCT00605852 - Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects Phase 1
Active, not recruiting NCT05960266 - Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study Early Phase 1
Completed NCT02256553 - Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) Phase 4
Completed NCT01007721 - Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season Phase 2
Completed NCT00932256 - Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients Phase 1
Completed NCT00384475 - A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413) Phase 3
Completed NCT00839189 - Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults Phase 1
Completed NCT00135629 - Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever Phase 3
Completed NCT04687059 - An Exploratory Study of PQ Grass 27600 SU Phase 2/Phase 3
Completed NCT00889460 - Safety and Tolerability Study of rBet v1 SLIT Tablets Phase 1
Completed NCT00396149 - Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1 Phase 1
Completed NCT00127647 - An Approved Drug to Study a New Indication for Allergic Rhinitis (0476-327) Phase 3
Completed NCT00659594 - Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406) Phase 3
Completed NCT01480271 - An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics. Phase 1